Table 6.
Case | Factor | OR for use of SF (95%CI) | P |
Uncomplicated-spine | |||
Hartsell Case 2 (1998, United States) | Respondents recommending doses < 30Gy: | NR | NR |
Longer time in practice | |||
Academic practice | |||
Practice in the Southwest | |||
Chow Case 2 (Canada, 2000) Chow Case 3 (Canada, 2000) | No differences based on country of specialty training or year training completed | NR | NR |
Fairchild Case 3 | University practice | 2.08 (1.35-3.19) | 0.001 |
(Intl, 2009) | Private practice | 0.27 (0.12-0.61) | 0.002 |
Trained in United States | 0.17 (0.10-0.28) | < 0.001 | |
Practice in Aust/NZ | 2.44 (1.43-4.18) | 0.001 | |
Roos Case 3 (Aust/NZ, 2000) | No difference based on trainees vs specialists, public vs private practice, years of experience, % workload palliative, between Aust vs NZ or between Aust states | NR | NR |
Complicated-neuropathic pain | |||
Fairchild Case 4 | University practice | 2.31 (1.33-4.00) | 0.003 |
(Intl, 2009) | Trained in US | 0.22 (0.11-0.43) | < 0.001 |
Roos Case 4 (Aust/NZ, 2000) | No difference based on trainees vs specialists, public vs private practice, years of experience, % workload palliative, between Aust vs NZ or between Aust states | NR | NR |
Aust: Australia; Intl: International; NR: Not reported; NZ: New Zealand.